Meridian Bioscience, Inc. (VIVO)
Upgrades & Downgrades
Latest VIVO news
Meridian Bioscience (VIVO) Moves 5.7% Higher: Will This Strength Last?
20 June 2022
Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ne...
Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference
23 May 2022
CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its partic...
3 Red-Hot Stocks That Could Continue to Beat the Market
12 May 2022
These three companies are among the few that have seen their shares rise so far this year.
Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History
6 May 2022
Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segments ahead of expectations, beating the consensus of $...
Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q2 2022 Results - Earnings Call Transcript
6 May 2022
Meridian Bioscience, Inc. (NASDAQ:VIVO ) Q2 2022 Earnings Conference Call May 6, 2022 10:00 AM ET Corporate Participants Charlie Wood - Vice President of Investor Relations Jack Kenny - Chief Executiv...
Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable
5 May 2022
Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed th...
Why Earnings Season Could Be Great for Meridian Bioscience (VIVO)
5 May 2022
Meridian Bioscience (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What Awaits Meridian Bioscience (VIVO) This Earnings Season?
3 May 2022
Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.
Meridian Bioscience (VIVO) Expected to Beat Earnings Estimates: Should You Buy?
29 April 2022
Meridian Bioscience (VIVO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.